SEP 5, 2026 · JOURNAL ARTICLE
Experimental radiotherapy with the gastrin-releasing peptide receptor (GRPR) antagonist [177Lu]Lu-AU-SAR-M1 in a prostate cancer murine model using reduced-frequency dosing
Biomedicine & Pharmacotherapy
Early-phase preclinical study in a murine xenograft model demonstrating proof-of-concept for a novel radiotherapeutic agent with two dosing schedules; results are encouraging but lack human translation, long-term follow-up, and mechanistic detail needed to guide clinical design.
Reported
Median survival (Control)37 d
Tumor eradication rate (treated g…50%
Dose per injection12 MBq